The effects of deucravacitinib on three cases of systemic sclerosis associated with psoriasis
- 9 January 2025
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 4067-4069
Abstract
No abstract availableKeywords
Funding Information
- Department of Clinical Cannabinoid Research
- Japan Cosmetic Association
- Japan Federation of Medium & Small Enterprise Organizations
This publication has 8 references indexed in Scilit:
- Utility of nailfold capillary assessment for predicting psoriatic arthritis based on a prospective observational cohort studyRheumatology, 2022
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialJournal of the American Academy of Dermatology, 2022
- Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine modeleLife, 2021
- Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathwayAnnals of the Rheumatic Diseases, 2016
- The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisArthritis & Rheumatology, 2016
- Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase DomainJournal of Biological Chemistry, 2015
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2013
- Development and evaluation of FSSG: frequency scale for the symptoms of GERDJournal of Gastroenterology, 2004